1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
MagForce AG

MagForce AG

MGFRF
MagForce AGUS flagOther OTC
0.00
USD
- -
- -
11,973.00Market Cap
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
Revenue per Share
- -
- -
0.01
- -
- -
- -
0.1
0.02
0.03
- -
0.03
0.02
- -
Basic EPS, GAAP
-1.08
-1.9
-2.08
-1.08
-0.07
-0.04
-0.06
-0.28
-0.28
0.16
-0.32
0.5
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-3.19
-4.93
-6.71
-6.06
-0.64
0.95
0.89
-0.91
-1.14
-0.97
-1.19
-0.57
- -
Tangible Book Value per Share
-2.53
-3.05
-0.01
- -
0.64
0.95
0.89
0.61
0.5
0.68
0.5
1.15
- -
Basic Weighted Avg Shares
4
4
4
5
24
26
26
26
26
26
28
29
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
3
- -
1
- -
1
1
- -
Operating Margin (%)
- -
- -
-16,506.99
- -
- -
- -
-103.46
-1,468.42
-590.81
10,411.27
-694.76
3,169.42
-1,707.62
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
Net Income, GAAP
-4
-7
-9
-6
-2
-1
-2
-7
-7
4
-9
15
-11
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.04
- -
0.02
- -
Profit Margin (%)
- -
- -
-20,946.92
- -
- -
- -
-60.05
-1,526.31
-1,042.45
6,485.2
-1,039.44
2,374.12
-3,004.19
Working Capital
-11
-13
-1
15
9
10
5
-2
- -
2
-1
- -
-5
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
5
16
17
23
26
Total Equity
-10
-12
- -
- -
15
24
23
16
13
18
15
36
27
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
26.54
- -
43.56
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-35.7
- -
-345.99
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
-6.54
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
24%
-24.42%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-61.82%
-179.22%
-171.71%
Sales/Revenue/Turnover
- -
208.21%
-43.33%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
1
2020
- -
- -
- -
- -
1
2021
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
-0.32
2020
- -
- -
- -
- -
0.5
2021
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Benjamin J. Lipps
Full Time Employees
33
Sector
Healthcare
Industry
Medical - Devices
Address
Max-Planck-Strasse 3 Berlin Germany 12489
IPO Date
Aug 24, 2018
Website
magforce.com
Similar Companies
Titan Medical Inc. (TMD.TO)
BioElectronics Corporation (BIEL)
TruScreen Group Limited (TRU.NZ)
iRhythm Technologies, Inc. (IRTC)
Boule Diagnostics AB (publ) (BOUL.ST)
Perseon Corporation (PRSN)
Business
MagForce AG, a Berlin-based medical technology company founded in 1997 as a spin-off from Charité – Universitätsmedizin Berlin, develops and commercializes nanotechnology-based therapies for solid tumor treatment through magnetic hyperthermia; its core NanoTherm therapy system comprises NanoTherm, a superparamagnetic iron oxide nanoparticle ferrofluid injected intratumorally; NanoActivator, an applicator generating alternating magnetic fields to induce hyperthermic tumor ablation up to 70 degrees Celsius; and NanoPlan, therapy planning software simulating temperature distribution. The company targets glioblastoma and other solid tumors, with CE-marked approval since 2010 for brain tumor applications delivered at NanoTherm centers in German university hospitals including Charité Berlin, Münster, Kiel, Cologne, and Frankfurt, as well as a mobile unit in Poland; it operates primarily in Europe via subsidiaries like MagForce USA Inc. for US clinical advancement in prostate cancer focal ablation. Following financial challenges, MagForce filed for insolvency proceedings in July 2022 with official opening in October 2022, leading to near-total share value loss, delisting from the Frankfurt Stock Exchange, and suspension of operations, with its OTC ticker MGFRF reflecting negligible trading value into 2025 amid ongoing restructuring discussions.